Subsequent Events

3 Months Ended

Mar. 31, 2026

Subsequent Events

Subsequent Events

13. Subsequent Events

Asset Purchase Agreement and Related Agreements with Janssen Pharmaceuticals, Inc.

On April 15, 2026, the Company entered into an asset purchase agreement with Janssen to reacquire all rights, title and interest in botaretigene sparoparvovec (bota-vec) and other assets related to the RPGR Product. In connection with this transaction, the Company agreed to make an upfront cash payment of $25.0 million, as well as certain future milestone and royalty payments tied to regulatory approval and commercial performance. Concurrently, the parties entered into the Termination Agreement that terminated the Original Asset Purchase Agreement, the Supply Agreement and certain other documents related to the Original Asset Purchase Agreement.

As a result of the termination of these agreements, all remaining rights and obligations under the prior arrangements, including any remaining performance obligations and related deferred revenue balances and outstanding accounts receivable balances as of March 31, 2026 are expected to be impacted and will no longer be recognized as originally anticipated. Certain provisions of the prior agreements may survive in accordance with their terms or as set forth in the Termination Agreement.

For additional information regarding the repurchase of the RPGR Product, see Note 1. The Company is currently evaluating the accounting impact of these transactions, including the treatment of previously recognized deferred revenue and related balances.

Equity Issuance

On April 17, 2026, the Company completed a public equity offering of 11,111,111 ordinary shares at a price of $9.00 per share, resulting in gross proceeds of approximately $100.0 million and estimated net proceeds of $93.3 million, after deducting underwriting discounts, commissions and offering expenses payable by the Company. The net proceeds from the offering are expected to be used for general corporate purposes, including working capital and capital expenditures.

Initial Closing of Strategic Collaboration with Hologen

On April 20, 2026, the Company completed the initial closing of its strategic collaboration with Hologen. In connection with the initial closing:

●

The Company, Hologen and/or certain of their affiliates entered into amendments to the Neuro Framework Agreement and the Manufacturing Framework Agreement to reflect certain pre-closing transactions and updated terms of the collaboration;

●

The Company, Hologen and certain of their affiliates entered into the Hologen Collaboration Agreement for the research, development, manufacture and commercialization of the Clinical Programs and the Delivery Device; and

●

In April 2026 prior to the Initial Closing Date, equity interests were issued in Hologen Neuro AI and MeiraGTx Manufacturing in consideration for the $105.0 million in payments Hologen previously made to the Company as part of the Upfront Payment under the Framework Agreements, resulting in Hologen owning a majority ownership interest in Hologen Neuro AI and a minority ownership interest in MeiraGTx Manufacturing.

Following the Hologen Initial Closing Date, Hologen has also committed to fund the remaining portion of the Upfront Payment provided for under the Framework Agreements.

For additional information regarding the initial closing of the strategic collaboration with Hologen, see Note 1. The Company is currently evaluating the accounting treatment of these transactions.

Debt Financing

On May 12, 2026, the Company, as issuer, and the Subsidiary Guarantors, the noteholders and other parties from time to time party to the Notes Purchase Agreement, and Perceptive, as administrative agent and lender under the Notes Purchase Agreement, entered into Amendment No. 5 to Amended and Restated Notes Purchase Agreement to extend the maturity date of the Notes Purchase Agreement from May 2, 2027 to July 1, 2027.